Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

IASO Completes $108 Million C Round for Novel Cell Therapies

publication date: Sep 16, 2021

IASO, a Nanjing biopharma, completed a $108 million Series C round to advance its novel cell therapy and biologic products for oncology and autoimmune diseases. The company will use the proceeds to develop its cell therapy portfolio and develop a pipeline of universal allogeneic cell therapies to treat solid tumors. The C round was led by CDH Baifu, and included CCB International, with participation from Everbright Limited, Co-Stone Capital, CNCB Capital and Plaisance Capital. Since its founding in 2017, IASO Bio has raised more than $178 million. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here